Our core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose disease from a single drop of blood.


This technology is applicable to a wide range of diseases, including prostate, brain, pancreatic, and blood cancers as well as cardiovascular and neuro-degenerative diseases.


ClarityDX Prostate, our lead product currently in development, is set to be the most accurate test to predict aggressive prostate cancer and is positioned to emerge in the near future as the world’s leading diagnostic tool to transform the management of prostate cancer.


Nanostics is a Canadian company with offices in Edmonton, Alberta. The company is privately held by the founders and a small group of investors.

Please contact us for information about opportunities to invest in Nanostics.

Nanostics corporate brochure October 1, 2018

Our success would not be possible without the support of our many Canadian and international collaborators, funders and partners.